Healthcare· Drug Manufacturers - Specialty & Generic· US
Latest observed price
$22.43
Session change unavailable
Market closed · NYSE
Status checked Oct 24, 2026, 11:52 PM · America/New_York
Observed Sep 21, 2026, 7:59 PM UTC · Last available price
The latest observed price above is market data. Forecast starting prices are issuance-frozen values and are labelled separately in Model Forecast below.
Elanco Animal Health Incorporated (ELAN) stock forecast and scoring
Review the dated model forecast and five-factor Scorecard for ELAN. Each has its own availability and reference date; a score is a relative comparison, not a price prediction.
12M forecast summary
Target date · Sep 21, 2027
Lower Estimate (P10)
$13.78
-38.6%
Median Estimate (P50)
$25.21
+12.4% from starting price
Upper Estimate (P90)
$37.23
+66.0%
$13.78Median $25.21$37.23
Median Estimate
$25.21
Starting price
$22.43
Change from starting price
+12.4%
Target date
Sep 21, 2027
Data through
Sep 21, 2026
The estimate uses its dated starting price. It does not predict returns from today’s quote.
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Similar Stocks
Research snapshot
Loading research…
Risk / safety methodology: Safety describes recent price swings and distance from a recent high alongside cash flow and profitability. It is not a credit rating or a promise of protection from loss.
Scoring · Elanco Animal Health Incorporated (ELAN) stock scorecard
Multi-factor scoring at a glance
Individual factor readings · Shading shows available dimensions only. Overall requires all five scores and a comparable peer group.
Sector · Sector averages available for 0 of 5 dimensions. Sector Avg.
How its valuation measures compare with the group.
Quality
Plus or Pro
How its profitability and operating quality compare.
Safety
41.2
0255075100
Moderate
How its price swings, distance from a recent high, cash flow and profitability compare.
Momentum
33.8
0255075100
Weak
How its recent price-trend measures compare.
Company snapshotDescriptive peer comparisonScore date: Sep 22, 2026Historical snapshot
All scores in this Scorecard describe relative characteristics as of the shown date, using historical market data and reported company information; higher scores on the 0–100 scale indicate more favorable characteristics in the relevant comparison group, and none forecasts future performance.
Scores are relative comparisons, not absolute grades: companies with different coverage may be scored on different inputs. Peer positions and input coverage can differ by factor; use the displayed comparison group and date when comparing readings. An 80 is not an 80% chance of a price rise. These scores are not price forecasts or recommendations.
The rank with complete inputs compares only companies with every input for that factor, using the issued scores. Equal partial coverage percentages do not establish matching inputs. Current stockwide snapshots use matching input groups; older snapshots may use a smaller fixed group. Scores do not separately adjust for industry or company size. Growth readings do not establish multi-year persistence or separate share-count effects from EPS growth. Scores are independent of the selected forecast horizon.
Research snapshot
Latest update · 2026-09-21
View Plans to read the previous successful update.
Previous update means the last successfully published update, including across weekends and market holidays. The Analysis tab keeps the information used in its latest report.
Research starting points
Open a ready-made screen, review its filters and adapt it to your questions.
Start with profit, cash generation and financial flexibility. Scores describe relative characteristics and do not predict returns.
Revenue · trailing 12 months
$5.02B
2025-07-01 to 2026-06-30
Net income · trailing 12 months
-$199M
2025-07-01 to 2026-06-30
Free cash flow · trailing 12 months
$379M
2025-07-01 to 2026-06-30
Consolidated debt
$3.92B
At 2026-06-30
Dates and reporting periods
Market observations, financial reporting periods and report dates can differ. Each measure shows its own period.
Research data through 2026-09-21
Update published 2026-09-22
Currency: USD
Company comparison
Compare company metrics only when their currency, observation date and reporting periods agree. Similar companies are starting points for research, not substitutes for each other.
12-month forecasts show model median estimates (P50), with changes from each forecast’s starting price. Headline scores describe dated company characteristics; they do not predict future performance.